Stock TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Teva Pharmaceutical Industries Limited

Equities

TEVA

US8816242098

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-10 pm EDT 		5-day change 1st Jan Change
16.25 USD +1.56% Intraday chart for Teva Pharmaceutical Industries Limited +16.24% +55.65%
May. 08 Sector Update: Health Care Stocks Slipping Wednesday Afternoon MT
May. 08 Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,702 10,576 8,835 10,129 11,703 18,405 - -
Enterprise Value (EV) 1 35,634 34,318 29,713 28,540 28,310 33,331 30,814 28,285
P/E ratio -10.8 x -2.65 x 21.1 x -4.3 x -20.9 x 17.3 x 12 x 9.58 x
Yield - - - - - - - -
Capitalization / Revenue 0.63 x 0.63 x 0.56 x 0.68 x 0.74 x 1.16 x 1.12 x 1.09 x
EV / Revenue 2.11 x 2.06 x 1.87 x 1.91 x 1.79 x 2.09 x 1.87 x 1.68 x
EV / EBITDA 7.61 x 6.99 x 6.05 x 6.21 x 5.88 x 7.02 x 6.05 x 5.36 x
EV / FCF 17.4 x 53.8 x 126 x 27.4 x 33.6 x 13 x 8.88 x 8.31 x
FCF Yield 5.76% 1.86% 0.79% 3.65% 2.97% 7.72% 11.3% 12%
Price to Book 0.77 x 1.05 x 0.86 x 1.28 x 1.56 x 1.92 x 1.55 x 1.28 x
Nbr of stocks (in thousands) 1,092,089 1,095,972 1,103,007 1,110,645 1,120,971 1,132,641 - -
Reference price 2 9.800 9.650 8.010 9.120 10.44 16.25 16.25 16.25
Announcement Date 2/12/20 2/10/21 2/9/22 2/8/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 16,887 16,659 15,878 14,925 15,846 15,920 16,488 16,862
EBITDA 1 4,685 4,912 4,911 4,598 4,818 4,751 5,091 5,277
EBIT 1 4,142 4,388 4,401 4,139 4,361 4,259 4,609 4,780
Operating Margin 24.53% 26.34% 27.72% 27.73% 27.52% 26.75% 27.95% 28.35%
Earnings before Tax (EBT) 1 -1,265 -4,406 658 - -624 -99 3,194 3,302
Net income 1 -999 -3,990 417 -2,353 -559 820.4 1,387 1,622
Net margin -5.92% -23.95% 2.63% -15.77% -3.53% 5.15% 8.41% 9.62%
EPS 2 -0.9100 -3.640 0.3800 -2.120 -0.5000 0.9401 1.349 1.695
Free Cash Flow 1 2,053 638 236 1,042 842 2,573 3,468 3,403
FCF margin 12.16% 3.83% 1.49% 6.98% 5.31% 16.16% 21.04% 20.18%
FCF Conversion (EBITDA) 43.82% 12.99% 4.81% 22.66% 17.48% 54.16% 68.12% 64.5%
FCF Conversion (Net income) - - 56.59% - - 313.64% 250.09% 209.81%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/12/20 2/10/21 2/9/22 2/8/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,100 3,661 3,786 3,595 3,884 3,661 3,878 3,850 4,457 3,819 4,020 4,030 4,104 3,743 3,982
EBITDA 1 1,373 1,135 1,134 1,089 1,240 899 1,125 1,134 1,660 1,005 1,177 1,220 1,301 - -
EBIT 1 1,248 1,013 1,019 977 1,130 785 1,011 1,020 1,546 892 1,053 1,096 1,156 1,027 1,121
Operating Margin 30.44% 27.67% 26.91% 27.18% 29.09% 21.44% 26.07% 26.49% 34.69% 23.36% 26.2% 27.2% 28.16% 27.45% 28.15%
Earnings before Tax (EBT) 1 -175 -971 -1,160 - -1,100 - - 75 507 -467 107 127 133 - -
Net income 1 -159 -955 -232 56 -1,221 -205 -863 80 461 -139 39 56.5 -15.77 - -
Net margin -3.88% -26.09% -6.13% 1.56% -31.44% -5.6% -22.25% 2.08% 10.34% -3.64% 0.97% 1.4% -0.38% - -
EPS 2 -0.1400 -0.8600 -0.2100 0.0500 -1.100 -0.1800 -0.7700 0.0700 0.4100 -0.1200 -0.3609 0.002380 0.8645 - -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/9/22 5/3/22 7/26/22 11/3/22 2/8/23 5/10/23 8/2/23 11/8/23 1/31/24 5/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 24,932 23,742 20,878 18,411 16,607 14,925 12,408 9,880
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 5.322 x 4.833 x 4.251 x 4.004 x 3.447 x 3.142 x 2.437 x 1.872 x
Free Cash Flow 1 2,053 638 236 1,042 842 2,573 3,468 3,403
ROE (net income / shareholders' equity) 18.3% 11.8% 28.1% 30.9% 37.9% 27.1% 29.6% 25.7%
ROA (Net income/ Total Assets) 4.45% 5.24% 5.81% 6.13% 6.62% 6.08% 7.53% 6.68%
Assets 1 -22,466 -76,212 7,179 -38,354 -8,438 13,486 18,413 24,302
Book Value Per Share 2 12.80 9.160 9.320 7.110 6.710 8.470 10.50 12.70
Cash Flow per Share 2 0.6900 1.110 0.7200 1.430 1.220 2.830 2.770 3.070
Capex 1 525 578 562 548 526 484 544 556
Capex / Sales 3.11% 3.47% 3.54% 3.67% 3.32% 3.04% 3.3% 3.3%
Announcement Date 2/12/20 2/10/21 2/9/22 2/8/23 1/31/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Teva Pharmaceutical Industries Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
16.25 USD
Average target price
17.24 USD
Spread / Average Target
+6.07%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED Stock Teva Pharmaceutical Industries Limited
+55.65% 18.41B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. Financials Teva Pharmaceutical Industries Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW